ViiV Healthcare has presented more than 20 abstracts of presentations at the 22nd International conference on AIDS (AIDS 2018), 23-27 July 2018 in Amsterdam. The data presented in this year relate mainly to new therapies and treatment strategies.
As new developments in the field of therapy of patients with HIV over the past few years the focus of research activities ViiV Healthcare is not only limited decrease in viral load. A new direction of research was the solution to the problem of potential outlying the risks and toxic reactions that may be associated with lifelong antiretroviral therapy. One solution to this problem – a comprehensive study of the possibility of reducing the number of components of therapy while maintaining its virological efficacy and high barrier to the development of resistance mutations.
As noted by John K. Potter, Jr., scientific, and medical Director of ViiV Healthcare: “the results of studies confirm the feasibility of further development of the two-component regime and strengthen our conviction that many patients can control the disease with two drugs instead of three and more.”
In the framework of the phase III studies GEMINI 1 and 2 of the two-component mode of therapy with dolutegravir and lamivudine compared with three-component regimen with dolutegravir plus fixed dose combination tenofovir/emtricitabine. Presents results on the primary endpoint of 48 weeks, indicating the effectiveness of the two-component mode of therapy with dolutegravir and lamivudine compared with three-component regimen in people living with HIV who have not previously received treatment.
Pedro Cahn, principal investigator of the research programme GEMINI, said: “over the last 15-20 years, the standard treatment for HIV has evolved a three-component regimes. Now, when we have more powerful drugs, the focus is shifting towards portability and ease of care. According to the results of studies of GEMINI, we can achieve the level of effectiveness of a three-component mode using the two-component regime. These results are important for patients with HIV who take drugs to suppress the activity of the virus throughout life. The results of these studies can potentially extend the paradigm of the use of these modes for the first-line treatment of patients with HIV.”
As noted by John K. Potter-ml.: “the Data presented at the AIDS conference 2018, further justify the need to reconsider the traditional approach to HIV treatment based on the use of three or more drugs. The results of the research programme GEMINI confirm our belief that the two component mode of therapy with dolutegravir, and lamivudine may be a valuable treatment option for patients who have not previously received treatment and that no patient should take more than the required amount of drugs.”
Source: GlaxoSmithKline (GSK)